SeaStar Medical Holding Corporation

reducing the amount of cash we need to raise to fund operations. Now, turning our efforts on the neutralized AKI trial, we completed the interim analysis, enabling us to understand early safety data and trends toward efficacy for our neutralized AKI pivotal trial of the selective cytophoretic device or SCD therapy. We also continue to add clinical sites to ensure we meet our new enrollment targets for the trial. In addition, We also announced today that we have opened the first site for the neutralized CRS clinical trial of the SCD therapy to treat patients with acute chronic systolic heart failure with cardiorenal syndrome, or CRS, awaiting left ventricular assist device, or LVAD, implantation. This is a small but very important market opportunity as it would potentially demonstrate the value of the SCD therapy in an indication outside of AKI. supporting its broad applications in many destructive hyper-inflammation conditions. Finally, we continued our disciplined effort to reduce costs while achieving strong operational results, and we raised over $12 million to strengthen our balance sheet and extend our financial runway. Now, before I turn the call over to Tim, I'd like to emphasize one last point. That is, the data we see and the stories we hear about how quell immune therapy has saved the lives of critically ill pediatric patients who in most cases have little hope of survival, are what drives our efforts to expand the use of this therapy to more children and to adults with similar conditions caused by destructive hyperinflammation. These market opportunities are significant, and we are working diligently to bring our lifesaving therapy to the patients whose chances of survival due to hyperinflammation are otherwise limited. And now, I will turn the call over to Tim to discuss our commercial achievements and market opportunities.

Thanks, Eric, and thanks, everyone, for joining us today on the C-Star Medical Third Quarter Call. Our goal for the Qualimmune launch this year has been to activate up to 20 new pediatric hospitals to drive product revenue, and as the numbers of centers increase, to provide a predictable stream of revenue as we move into 2026 and beyond. We currently have 10 active commercial pediatric hospitals that have completed all IRB approvals and have ordered product. adding four new customers since the beginning of the third quarter. We are working diligently to increase that number and expect additional new sites to be added by the end of this year. As Eric indicated, our fourth quarter product sales in the first six weeks already position us for revenue exceeding the third quarter net revenue. And it's important to note that we've seen an uptick in patients receiving qualimmune therapy. Our focus for the remainder of the year and into 2026 is to ensure all clinically appropriate patients receive Quell Immune therapy accounts and continue to move sites through the Quell Immune adoption process as quickly as possible. Specifically, we continue to leverage best practices learned throughout the launch of Quell Immune to implement tactics related to brand awareness, clinical performance, and patient identification, such as supplemental clinical training, development of a speakers bureau, and development of patient care team forums to share ideas and overcome operational challenges typical to new product adoption within hospital systems. We've been able to leverage clinical and economic data as well through recent publications such as the cost savings model published in the Journal of Medical Economics and real world data presentation from our patient registry illustrating the survival benefit of qualimmune therapy when added to CRRT in pediatric AKI. Importantly, we believe that the patient population for this therapy is far broader than it's used today. Beyond expanding use in our active accounts, we are working to remove hurdles to the adoption process for new target accounts. While the high-level process to Quell Immune Adoption is the same for all hospital systems, how these sites work through the process can vary and how they are structured from a clinical care and administrative perspective. We continue to refine the operational process of Quell Immune Adoption and attempt to simplify this process for the customer. For example, Before we have our first meeting with a new system interested in Quell Immune, we diligently work to identify and include key staff, such as nephrology, critical care, nursing, procurement, research, and many more. This may sound obvious, but in many cases, the primary investigator and advocate sponsoring Quell Immune for their system isn't fully aware of these staff members. Getting these people in a conference with us all at the same time ultimately shortens the adoption curve as we are able to identify point people, share cross-functional requirements, and allocate specific tasks to be completed in parallel. It is a symphony at work with many role players, and the good news is that we are beginning to see an impact of these efforts, and we recently were able to add a leading pediatric institution in a six-month time frame. While still not the norm, it's great progress, and everything we learn in this launch will benefit Seastar Medical in future commercial launches as well. And finally, with our early registry data in hand, we have approached the FDA to request relief from the mandatory registry. We are very hopeful that the FDA will agree to this request and believe they will be aligned with accelerating adoption of Quell Immune to potentially save more lives. Turning to the market, we have great expectations for 2026 to help patients by delivering Quell Immune Therapy to more pediatric hospital systems. We are relentlessly focused on adding new sites as quickly as possible, and the more sites we add, the more we de-risk our revenue variability and ultimately generate a predictable and reliable revenue stream for our investors and Seastar Medical. That's our goal. We believe that we will capture a sizable portion of this small but important market, and our estimates put the total U.S. market at about $100 million, and capturing even a small double-digit percent of this market creates significant value for our stockholders and delivers important revenue for Seastar Medical. And with that, I'll turn the presentation over to our Chief Medical Officer, Kevin Chung. Kevin?

Thanks, Tim. and thank you to everyone joining us today. I'm pleased to report continued momentum in our neutralized AKI pivotal trial. Since the start of Q3, we've onboarded three additional clinical sites and enrolled 21 more patients, bringing a total enrollment to 146 of our new target of 339 patients. For those less familiar, neutralized AKI is a randomized control trial designed to assess whether up to 10 sequential 24-hour STD treatments can improve 90-day survival or renal recovery in critically ill patients with acute kidney injury requiring CRRT. The primary endpoint is a composite of mortality or dialysis dependence at 90 days. As planned, we conducted a pre-specified interim analysis at the 100-patient milestone to assess safety and confirm our statistical powering assumptions. I am pleased to share that the Independent Data Safety Monitoring Board, or DSMB, determined the STD therapy to be safe, with no device-related adverse events observed in the treatment arc. This finding is particularly important in the ICU setting, where patients are often critically ill, immune compromised, and subject to multiple organ support modalities. In this fragile population, even minor safety concerns can have serious clinical consequences, and they often become gating factors for regulatory review and clinical adoption. That is why demonstrating a clean safety profile is not just a trial milestone, but a critical foundation for physician confidence, FDA interaction, and future uptake in real-world care. We're encouraged that SCD continues to show this level of safety in such high-risk environments. As we have previously disclosed, the interim analysis revealed that the assumed effect size of 20% was not observed at this point. While there was a clear signal of clinical benefit, it was not large enough to achieve statistical significance with the originally planned sample size of 200. Based on this, In accordance with the trial's statistical analysis plan, the DSMB recommended increasing the total enrollment to 339 patients to ensure adequate power to detect meaningful efficacy. Let me be clear. The DSMB observed a clear and encouraging signal of benefit. The recommendation to expand enrollment is a positive step forward, grounded in data and consistent with our commitment to rigorous clinical science. By increasing the sample size, we are enhancing the statistical power of the study and positioning ourselves to generate results that are more robust, more credible, and more likely to drive regulatory and clinical acceptance. This is a strategic recalibration and one that strengthens our confidence in the ultimate success of the trial. We have already acted on the DSMB's recommendation. In addition to our 17 active sites, we have begun activating eight more centers to help us meet our new target. Our team, along with our academic and clinical partners, is working with urgency and precision. We understand what's at stake, and we are committed to completing enrollment by the end of 2026. Let me now turn to our SAVE surveillance registry, which tracks commercial use of our Quell Immune Therapy in critically ill children. At the recent Fifth International Symposium on Acute Kidney Injury in Children, we presented encouraging early results from 21 pediatric patients treated under real-world conditions for life-threatening AKI and sepsis. Among these high-risk patients, many treated as a last resort, 76% survived through 60 days and 71% through 90 days. As a critical care physician, I find these outcomes remarkable. These were children on the brink of death. While the numbers are still small, the signal is undeniable. Quell Immune is giving these patients a fighting chance. These clinical data Coupled with our previous clinical study data we originally submitted to the FDA, now totals 43 children with over 75% survival, clearly demonstrating the value of the therapy. I would also like to share a unique aspect of how we are learning from the real-world use of Quell Immune. Every month, we host a Quell Immune users call, a forum attended by both current and prospective clinical users. During these sessions, we have discussed nearly every patient treated under the SAVE surveillance registry. The story shared of our device stabilizing a critically ill child, in many cases reversing acute decompensation, are not only clinically powerful, but deeply meaningful to all of us at Seastar Medical. These discussions are not just anecdotal. They provide critical insights that complement our registry data and inform best practices. At the same time, we're continuing to share pooled outcomes with the broader pediatric nephrology and critical care communities. These real-world results are more than encouraging. They reinforce both the lifesaving potential of our therapy and the mission that drives our entire organization. Lastly, I'd like to highlight the launch of our neutralized CRS trial, which evaluates SCD in patients with chronic systolic heart failure complicated by cardiorenal syndrome, who are not candidates for heart transplant or even LVAD, or left ventricular assist device. The single arm feasibility study will enroll 20 patients in the ICU setting with the goal of demonstrating improvement in renal and cardiac function prior to any mechanical support intervention. One of the main differences in this treatment is the length of SCD treatment versus the neutralized AKI study. These patients are treated intermittently for up to six hours daily for up to six days. In the neutralized AKI study, the patients are treated continuously for 24 hours daily for up to 10 days. This is important because this could demonstrate the feasibility of intermittent therapy bridging to more outpatient settings in a broad range of chronic hyperinflammatory diseases. If successful, neutralized CRS could pave the way for a separate marketing application to the FDA, opening the door to a new acute therapeutic intervention with a different dosing regimen while setting the foundation towards entry into chronic conditions in outpatient-based therapy. As Eric noted earlier, this trial is part of our broad strategy to bring SCD therapy to multiple indications. Whether in AKI, CRS, or beyond, we believe our platform has the potential to transform outcomes in all patients impacted by hyperinflammation. With that, I'll hand it over to our controller, Brad Towne.